Relapse proves treatment failure and lack of willpower

The claim

The willpower theory of addiction holds that relapse represents a failure of personal commitment: the patient did not try hard enough, did not want recovery badly enough, or made a deliberate choice to use again. Under this logic, treatment failure is the patient’s fault, not a feature of underresourced or poorly designed treatment systems. Funding for addiction services, harm reduction, and supervised consumption is therefore wasted on people who will not use it responsibly.

The mechanism

Addiction meets the clinical criteria for a chronic brain disorder. Nora Volkow, Joanna Fowler, and George Koob’s decades of neuroimaging research — summarized in Volkow & Koob (2015, New England Journal of Medicine) — established that repeated exposure to addictive substances produces lasting neuroadaptation in three brain circuits: the basal ganglia (habit and reward), the extended amygdala (stress and compulsion), and the prefrontal cortex (executive function and impulse control). These changes are visible on PET imaging and persist long after acute withdrawal. They explain craving, compulsive use, and vulnerability to relapse under stress — not as character defects but as predictable neurobiological sequelae of exposure. The National Institute on Drug Abuse (NIDA) formally classifies addiction as a chronic brain disorder on this evidence basis.

Relapse rates are identical across chronic diseases where willpower is not invoked. McLellan, Lewis, O’Brien, and Kleber’s 2000 paper in JAMA presented a direct comparison of compliance and relapse rates across four conditions: addiction, hypertension, type 2 diabetes, and asthma. Relapse rates were 40–60% for addiction, 50–70% for hypertension, 30–50% for type 2 diabetes, and 50–70% for asthma. Medication adherence rates were similarly comparable. No clinician argues that a diabetic who fails to maintain glycemic control through diet alone lacks willpower; the clinical response is to adjust treatment. The double standard applied to addiction — in which relapse triggers moral condemnation, loss of housing, loss of employment, and criminal prosecution rather than treatment revision — is itself a structural feature with measurable mortality consequences.

Structural triggers dominate the relapse landscape. SAMHSA and NIDA research identifies the most common proximate causes of relapse: housing instability, untreated chronic pain, unemployment, re-exposure to environments associated with prior use, and co-occurring untreated mental health conditions (particularly PTSD and depression). These are not failures of will. They are structural features of the lives of people with addiction — features that are amenable to policy intervention. Housing First programs, which provide stable housing without sobriety preconditions, show consistent reductions in substance use and mortality (Padgett et al., 2011). This is a structural intervention with documented effect on a condition framed as an individual moral failure.

Portugal’s decriminalization experiment is the strongest quasi-experimental evidence. In 2001, Portugal decriminalized personal possession of all drugs and redirected criminal-justice funds into treatment, harm reduction, and social reintegration services (housing, job placement). National drug-induced death rates fell from approximately 80 per million in 2001 to 4 per million by 2017 — a 95% reduction over 16 years — while European neighbors saw rising overdose mortality (Hughes et al., 2019, International Journal of Drug Policy; EMCDDA data). HIV infection among people who inject drugs fell from 52% of new cases in 2000 to 7% by 2015. The confound is that Portugal changed multiple policy elements simultaneously; but the magnitude and duration of the effect, sustained across multiple governments and economic cycles, is difficult to explain without crediting the structural change.

Switzerland’s randomized heroin-assisted treatment trial removes willpower as a variable. Beginning in 1994, Switzerland conducted a randomized controlled trial of heroin-assisted treatment (HAT) for people who had failed methadone maintenance. Participants received pharmaceutical-grade heroin under medical supervision at clinic sites. Rehm et al. (2001, European Addiction Research) and Killias et al. (2002) documented that street crime among participants fell approximately 60% and unemployment fell approximately 82% during HAT. These are not improvements in willpower; they are direct consequences of removing the structural conditions — illegal market dependence, criminal risk, poverty — that drive compulsive use and crime. Switzerland subsequently institutionalized HAT as a standard treatment option, and the program has operated for three decades.

Who benefits

Private insurance companies benefit from the willpower frame because it justifies benefit limits for addiction treatment: if relapse means the treatment failed, payers are not obligated to fund repeated treatment episodes. Despite the Mental Health Parity and Addiction Equity Act (2008), coverage for addiction treatment remains substantially less comprehensive than coverage for comparably prevalent physical health conditions in practice. Criminal justice systems benefit because the framing justifies incarceration rather than treatment for drug offenses — a cheaper-appearing response that produces higher recidivism and costs more long-term. The absence of publicly funded treatment infrastructure benefits those who profit from the current system’s fragmentation: private for-profit treatment facilities that charge out-of-pocket rates, bail bond companies, and prison contractors.

The data

Portugal: Before vs. after decriminalization (2001)

US treatment access (SAMHSA NSDUH 2021): Of the approximately 46 million Americans who met criteria for a substance use disorder in 2021, only 10.3% received any treatment. The leading reason given for not seeking treatment: cost and lack of coverage.

Comparators

Portugal decriminalized all personal drug possession in 2001 and invested the savings in treatment and harm reduction. Drug-induced mortality fell 95% over 16 years. This is the strongest real-world evidence that structural intervention — not willpower — drives outcomes.

Switzerland operates a federally authorized heroin-assisted treatment program for people with opioid use disorder who have not responded to oral substitution therapy. Participants attend clinics twice daily to receive pharmaceutical heroin. The program has operated since 1994 and is associated with dramatically reduced crime, improved employment, and near-elimination of HIV transmission among participants. It requires zero willpower to ‘just stop’ — it meets people where they are.

Canada has approved supervised consumption sites in multiple cities (Vancouver’s Insite being the most studied), provides naloxone without prescription, and has expanded buprenorphine/naloxone access through pharmacist prescribing. Insite is associated with a 35% reduction in overdose mortality in its catchment area (Milloy et al., 2008, Lancet) without increasing drug use in the surrounding community.

Germany treats opioid use disorder primarily through substitution therapy (methadone, buprenorphine) available through primary care physicians without the US’s historical waiver requirements. Heroin-assisted treatment is available for treatment-resistant cases. Germany’s drug-induced mortality rate is substantially lower than the US rate on a per-capita basis.

The counter

The honest steelman acknowledges that individual agency is not zero. People in similar structural circumstances make different choices about substance use, and some people achieve sustained recovery through motivation-based approaches (12-step programs, SMART Recovery, brief interventions). The neurobiological evidence does not eliminate agency — it complicates a simple willpower frame without negating it entirely.

More substantively: some addiction researchers argue that the ‘chronic relapsing brain disease’ model may inadvertently reduce self-efficacy, since people who believe they have a permanent brain disease may feel less capable of recovery through their own efforts (Lewis, 2015, Biology of Desire). The chronic disease model also has been critiqued for medicalizing what is partly a social phenomenon — the role of community, meaning, and connection in recovery (the ‘rat park’ experiments of Alexander et al., 1981).

These are real tensions. The weight of natural experimental evidence, however, comes down heavily on the side of structural factors as primary determinants of population-level addiction outcomes. The individual variation that willpower accounts for operates at the margins of a distribution shaped by structural conditions.

References

McLellan, A. T., Lewis, D. C., O’Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA, 284(13), 1689–1695. https://doi.org/10.1001/jama.284.13.1689

Volkow, N. D., & Koob, G. (2015). Brain disease model of addiction: Why is it so controversial? The Lancet Psychiatry, 2(8), 677–679. https://doi.org/10.1016/S2215-0366(15)00236-9

Hughes, C. E., Matias, J., & Griffiths, P. (2019). Evaluating the effects of drug policy on public health. International Journal of Drug Policy, 74, 1–5. https://doi.org/10.1016/j.drugpo.2019.09.007

Rehm, J., Gschwend, P., Steffen, T., Gutzwiller, F., Dobler-Mikola, A., & Uchtenhagen, A. (2001). Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. European Addiction Research, 7(3), 138–145. https://doi.org/10.1159/000052400

SAMHSA. (2022). 2021 National Survey on Drug Use and Health: Key substance use and mental health indicators in the United States. Substance Abuse and Mental Health Services Administration.

Padgett, D. K., Stanhope, V., Henwood, B. F., & Stefancic, A. (2011). Substance use outcomes among homeless clients with serious mental illness: Comparing Housing First with treatment first programs. Community Mental Health Journal, 47(2), 227–232. https://doi.org/10.1007/s10597-009-9283-7

NIDA. (2020). Drugs, brains, and behavior: The science of addiction. National Institute on Drug Abuse. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction